Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

University of Minnesota incobotulinumtoxinA tinnitus study

Also known as: Incobotulinum toxin A, IncobotulinumtoxinA, Xeomin, NCT05650645

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Biologic

Stage

Phase 2

Status

Completed

Target Gene

—

Route / Mode

Auricular muscle injections

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United States

Population

adult, tinnitus, repurposed-drug

Trial IDs

Mechanism

Completed randomized Phase 2 trial evaluating incobotulinumtoxinA injections into auricular muscles for tinnitus relief using Tinnitus Handicap Inventory outcomes.

Indications

Tinnitus

Notes

Corrected from a generic toxin row to a completed University of Minnesota tinnitus trial. The registry supports a study-level record only; no commercial tinnitus indication or product program was verified.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT05650645

Open

Key Events

2023-01-01

IncobotulinumtoxinA tinnitus study started

2025-12-29

Registry lists study completion date

Clinical Trials (1)